Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinoma-derived neurons genetically engineered to produce glial cell line-derived neurotrophic factor.
OBJECTIVE
The P19 embryonal carcinoma-derived cell line consists of undifferentiated multipotential cells, which irreversibly differentiate into mature neurons after exposure to retinoic acid (RA). In the present study, the authors genetically engineered P19 cells to produce glial cell line-derived neurotrophic factor (GDNF), and grafted the cells in a rat model that had been rendered parkinsonian.


METHODS
Undifferentiated P19 cells were grown in vitro and transduced with GDNF complementary DNA. The level of GDNF released from the transduced cells was measured using an enzyme-linked immunosorbent assay, and its neurotrophic activities were assessed by testing the effects on rat embryonic dopamine (DA) neurons in culture. After having been exposed to RA for 48 hours and allowed to differentiate into postmitotic neurons, the GDNF gene-transduced cells were implanted into the midbrain of immunosuppressed rats. A unilateral nigrostriatal lesion was then induced by intrastriatal infusions of 6-hydroxydopamine. Immunohistochemical analyses performed 4 weeks postgrafting revealed that the GDNF-producing cells expressed several neuronal markers without evidence of overgrowth. The grafts expressed GDNF protein and prevented the death of nigral DA neurons. Furthermore, the GDNF-producing cells implanted 4 weeks after nigrostriatal lesions restored the expression of tyrosine hydroxylase in injured DA neurons and induced their dendritic sprouting.


CONCLUSIONS
The results indicate that the P19 cell line transduced with the GDNF gene can stably secrete functional levels of GDNF, even after being converted to postmitotic neurons. Because it is has been established that GDNF exerts trophic effects on DA neurons, the means currently used to deliver GDNF into the brain could be a viable strategy to prevent the death of nigral DA neurons in cases of Parkinson's disease.
Nakao
N
N
Department of Neurological Surgery, Wakayama Medical College, Japan. nnakao@wakayama-med.ac.jp
Yokote
H
H
Nakai
K
K
Itakura
T
T
D000704:Analysis of Variance; D000818:Animals; D018236:Carcinoma, Embryonal / Q000235:genetics / Q000473:pathology*; D016923:Cell Death; D002454:Cell Differentiation / Q000187:drug effects; D002470:Cell Survival; D002478:Cells, Cultured; D003712:Dendrites / Q000648:ultrastructure; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D005500:Follow-Up Studies; D015971:Gene Expression Regulation, Enzymologic; D005818:Genetic Engineering; D008297:Male; D009414:Nerve Growth Factors / Q000235:genetics / Q000378:metabolism*; D009457:Neuroglia / Q000378:metabolism*; D009474:Neurons / Q000473:pathology* / Q000637:transplantation; D010300:Parkinson Disease / Q000601:surgery*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012038:Regeneration; D013234:Stem Cells / Q000187:drug effects / Q000473:pathology; D013378:Substantia Nigra / Q000473:pathology*; D014161:Transduction, Genetic / Q000235:genetics; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014446:Tyrosine 3-Monooxygenase / Q000235:genetics
D009414:Nerve Growth Factors; D014212:Tretinoin; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine